HealthTree Podcast: Cristina Gasparetto, MD Duke University & Mark Newman, OD

All cancer therapies come with some type of side effect. One newly approved therapy called BLENREP, by GSK, is an antibody drug conjugate targeting BCMA that can cause a condition called keratopathy. Keratopathy is an eye condition that can be mild, so patients don't even know they have it, or it can be more severe. Myeloma specialist Dr. Cristina Gasparetto, MD from Duke University and Mark Newman, OD of OPTIX Eye Center will share in this show how keratopathy can be successfully managed for patients on BLENREP. Learn what keratopathy is, how care is coordinated between the myeloma doctor and the eye doctor, and what patients should know about keratopathy before starting on this therapy. 

Thanks to our episode sponsor, Takeda Oncology